Development of anti-HIV peptides based on a viral capsid protein

被引:12
|
作者
Mizuguchi, Takaaki [1 ]
Ohashi, Nami [1 ]
Matsumoto, Daichi [1 ]
Hashimoto, Chie [1 ]
Nomura, Wataru [1 ]
Yamamoto, Naoki [2 ]
Murakami, Tsutomu [3 ]
Tamamura, Hirokazu [1 ]
机构
[1] Tokyo Med & Dent Univ, Inst Biomat & Bioengn, Chiyoda Ku, Tokyo 1010062, Japan
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117597, Singapore
[3] Natl Inst Infect Dis, AIDS Res Ctr, Shinjuku Ku, Tokyo 1628640, Japan
关键词
anti-HIV; capsid protein; chloroquine; octa-arginyl group; overlapping peptide; HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-PRODUCTS; CD4; MIMICS; INTEGRASE INHIBITORS; ENTRY INHIBITORS; MATRIX PROTEIN; LIFE-CYCLE; TYPE-1; POTENT; CXCR4;
D O I
10.1002/bip.22920
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Peptide inhibitors with cell permeability targeting an HIV-1 capsid (CA) protein might make therapeutic by regulating HIV-1 replication. Overlapping fragment peptide libraries covering the whole sequence of an HIV-1 CA protein have been synthesized with the addition of an octa-arginyl moiety to increase their cell permeability. Amongst these peptides, several compounds which inhibit the HIV-1 replication cycle have been found. Conjugation of cell-penetrating functions such as an octa-arginyl group to individual peptides in combination with the addition of chloroquine in cell-based anti-HIV assays was previously proven to be a useful assay method with which to search for active peptides. Anti-HIV assays have been performed in the presence or absence of chloroquine and found that most of compounds have higher anti-HIV activity in the presence, rather than in the absence of chloroquine. Some potent seeds as anti-HIV agents might naturally lie hidden in CA proteins, and could become useful leads to HIV inhibitors.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Update on Gilead Sciences Anti-HIV Development Programs
    Cihlar, Tomas
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2009, 51 : 91 - 91
  • [42] Anti-HIV Drug Development Through Computational Methods
    Wan-Gang Gu
    Xuan Zhang
    Jun-Fa Yuan
    The AAPS Journal, 2014, 16 : 674 - 680
  • [43] Development of Potent Anti-HIV Chimeric Immune Receptors
    Yang, Wen
    Lu, Li
    Junghans, Richard P.
    JOURNAL OF IMMUNOLOGY, 2007, 178
  • [44] Anti-HIV microbicide development: targeting the virus is the key
    O'Keefe, Barry R.
    FUTURE VIROLOGY, 2011, 6 (05) : 553 - 556
  • [45] Design and development of integrase inhibitors as anti-HIV agents
    Gupta, SP
    Nagappa, A
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (18) : 1779 - 1794
  • [46] An Algorithm for the Preclinical Development of Anti-HIV Topical Microbicides
    Buckheit, Robert W., Jr.
    Buckheit, Karen W.
    CURRENT HIV RESEARCH, 2012, 10 (01) : 97 - 104
  • [47] Mainstreaming Anti-HIV/AIDS measures in development cooperation
    Vuckovic, M
    Katzan, J
    Kirsch-Woik, T
    Girrbach, E
    XV INTERNATIONAL AIDS CONFERENCE: APPENDIX, 2004, : 75 - 80
  • [48] Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment
    Tsuji, Kohei
    Owusu, Kofi Baffour-Awuah
    Kobayakawa, Takuya
    Wang, Rongyi
    Fujino, Masayuki
    Kaneko, Moemi
    Yamamoto, Naoki
    Murakami, Tsutomu
    Tamamura, Hirokazu
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (11)
  • [49] Anti-HIV strategy
    Wilson, E
    CHEMICAL & ENGINEERING NEWS, 2006, 84 (14) : 14 - 14
  • [50] ANTI-HIV IMMUNOTOXINS
    PINCUS, SH
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 181 - 181